New August 2026 Study: GHK-Cu Gel for Skin Wound Healing

In August 2026, Hudson Biotech launched a new clinical trial investigating whether a topical gel containing GHK-Cu (the copper(II)-peptide complex glycyl-histidyl-lysyl-copper) can speed up skin wound healing in healthy adults. This article explains the trial design, the preclinical evidence that motivated it, and why GHK-Cu is a logical candidate for wound-healing research.

Trial design and objectives

Study identifier: NCT07437586 (ClinicalTrials.gov)

The trial is investigating whether a topical GHK-Cu gel can safely accelerate healing of small, standardized skin wounds in healthy adults compared to a matching vehicle (placebo) gel. Key design elements:

• Primary outcome: Wound closure rate (time to re-epithelialization) over ~14 days.
• Secondary outcomes: Safety, tolerability, collagen deposition, angiogenesis markers, and inflammatory biomarkers in wound exudate.
• Participants: Healthy adults; standardized suction blister wounds to ensure uniform injury.
• Rationale: Preclinical research has shown that GHK-Cu stimulates collagen synthesis, promotes blood vessel formation, and modulates inflammation — all critical to normal wound healing.

Why GHK-Cu for wound healing?

GHK-Cu has been investigated in wound-healing models for decades. The preclinical rationale is strong:

• Collagen synthesis: GHK-Cu stimulates fibroblast production of collagen I and III, essential for wound strength and remodeling.
• Glycosaminoglycan (GAG) upregulation: Increases dermatan sulfate and chondroitin sulfate, structural components of extracellular matrix.
• Angiogenesis: Promotes new blood-vessel formation through multiple pathways (VEGFR, TGF-β).
• Anti-inflammatory effects: Reduces TNF-α, IL-6, and other pro-inflammatory cytokines in wound sites.
• Antioxidant activity: Copper(II) in the complex may participate in free-radical scavenging.

Prior in vivo studies showed that GHK-Cu accelerated wound closure in rodent skin injury models by 18–36% and increased collagen deposition at days 18 and 22 post-wounding.

Improved formulations: Supramolecular GHK-Cu

Recent work has explored enhanced formulations to improve delivery and efficacy. Supramolecular metallopeptide hydrogels (Supra GHK-Cu) showed better wound healing acceleration compared to conventional GHK-Cu in animal models by:

• Increasing sustained release from the gel matrix
• Promoting higher collagen deposition
• Enhancing angiogenesis and cell proliferation more efficiently

This August 2026 trial likely leverages similar formulation advances to optimize topical delivery.

Translation from preclinical to clinical

This trial represents an important step in translating decades of GHK-Cu wound-healing research from cell culture and animal models into human outcomes. If successful, it could establish:

• Safety and tolerability of topical GHK-Cu in human skin
• Measurable acceleration of wound re-epithelialization in humans
• A quantifiable effect size and time-to-healing benefit

The use of standardized suction blisters (rather than natural wounds) ensures uniform injury size and depth, reducing variability and increasing statistical power to detect a GHK-Cu effect.

Sources & further reading

• ClinicalTrials.gov — Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586)
• ScienceDirect — Glycosaminoglycans and Small Proteoglycans in Wounds: GHK-Cu Modulation
• PMC/NIH — GHK Peptide: Natural Modulator of Multiple Cellular Pathways in Skin Regeneration

Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.